Should I buy JNJ (JNJ)?

What Strong Buy means for JNJ today

A Strong Buy rating is the output of the composite fair-value band ($245–$419) compared with the live price ($223), a 9/10 moat score, and a 88/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

JNJ is rated Strong Buy at $222.51 versus the reconciled fair value midpoint of $331.57, implying +49.01% upside/downside. Confidence is separately disclosed at 88/100. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 20%): target $419.09, return +88.3%. Base case (probability 60%): target $331.57, return +49.0%. Bear case (probability 20%): target $244.50, return +9.9%.

Probability weights are not symmetric. JNJ is a mature compounder stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for JNJ are: Talc Litigation Catastrophe; Stelara Biosimilar Collapse; Regulatory Price Controls. The single biggest risk is Talc Litigation Catastrophe: Settlements and ongoing liabilities breach the ring-fenced strategy, draining >$15B in free cash flow and triggering credit downgrades.

The biggest opportunity is Bull: Johnson & Johnson successfully bridges its impending patent cliffs with high-margin pipeline approvals. MedTech accelerates, and the market removes the litigation discount, rewarding the structural predictability with a premium multiple. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Strong Buy rating with 88/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/jnj/analysis.

Frequently asked questions